1
Clinical Trials associated with CI-135 CAR-T cells(Beijing Boren Hospital)First-in-Human (FIH), Open-Label, Non-Randomized, Single-Arm Phase 1 Study to Evaluate the Safety and Efficacy of CI-135 CAR-T Cells in Subjects with Relapsed or Refractory Acute Myeloid Leukemia
This is a FIH, single center, open label, non-randomized, single-arm, Phase I clinical trial to evaluate the safety and efficacy of CI-135 CAR-T cells in subjects with relapsed or refractory Acute Lymphoblastic Leukemia. This study is a dose-escalation study that includes 2 dose levels, and a total of 4-7 subjects will be enrolled. CI-135 CAR-T cells will be manufactured using PBMC collected from the subjects, and will be infused intravenously into subjects after lymphodepletion.
100 Clinical Results associated with CI-135 CAR-T cells(Beijing Boren Hospital)
100 Translational Medicine associated with CI-135 CAR-T cells(Beijing Boren Hospital)
100 Patents (Medical) associated with CI-135 CAR-T cells(Beijing Boren Hospital)
100 Deals associated with CI-135 CAR-T cells(Beijing Boren Hospital)